Omnicell Inc. Common Stock ($0.001 par value) (OMCL)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and sell at a discount to intrinsic value. Omnicell is a healthcare technology company serving hospitals with automated medication and supply systems. The good news is that it moved from a fiscal 2023 net loss of $20.4 million to fiscal 2024 net income of $12.5 million, though fiscal 2025 net income slipped to $2.1 million on $1.2 billion of revenue, or $0.04 per diluted share. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $312.2 million and net income was $24.3 million, or $0.52 per diluted share, up from $11.4 million and $0.25 in fiscal Q1 2026. That is real momentum, and trailing free cash flow of $126.8 million gives a 7.6% FCF yield, which is solid. The balance sheet is conservative with debt-to-equity of 0.15, and a Piotroski F-Score of 8/9 confirms improvement. But quality is still suspect: ROE is 3.06% and ROCE is 1.52%, far below what I want. At the 2026-10-13 close of $36.45, FairStock calculates a P/E of 43.39 and P/B of 1.29. The Graham Number is $23.14, so the price carries a negative 57.52% margin of safety. The Lynch category is a turnaround, and the FairStock Score is only 25/100. This is a speculative recovery, not a classic value bargain. I would need proof that the recent profit burst is durable before calling it attractive.

In plain English: Omnicell makes automated medication and supply management technology for hospitals and health systems. The business has swung back to profit and generates positive cash flow, but yearly profits are still thin, and the shares look expensive compared with the company's earnings and net assets. As of the 2026-10-13 close, the price appears richer than the underlying numbers justify.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer